Item 9.01 Financial Statements and Exhibits. ‌ (d) Exhibits Exhibit No. Description 3.1 First Amendment to Bylaws dated October 15, 2025 ──────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apimeds Pharmaceuticals US, Inc. Date: October 16, 2025 By: /s/ Erik Emerson Name: Erik Emerson Title: Chief Executive Officer